Zynerba fragile after pivotal failure
The implosion of Zygel’s fragile X study leaves its developer few places to turn.
Tisotumab’s cervical cancer efficacy falls off
But a 24% remission rate is still enough to get the project before the US regulator, analysts reckon.
Gilead finally prices its Covid-19 drug
By pricing remdesivir at $2,340 for a five-day course Gilead has kept investors on side, but others will be disappointed.
Medtech
Covid-19 divides the biggest medtechs
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Company Events
Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Important catalysts approach for smaller biotechs
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Interviews
Healthineers’ Covid-19 antibody test spikes an interest in vaccines
The German group has come late to antibody testing, but has punchy accuracy data and a possible means of neutralising some of the competition.
Making sense of Covid-19 treatment approaches
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
Zynerba hopes to crack fragile X at last
The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.